Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01-MedSci.cn

Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01

Javle, MM; Abou-Alfa, GK; Macarulla, T; Personeni, N; Adeva, J; Bergamo, F; Malka, D; Vogel, A; Knox, JJ; Evans, TRJ; Dimova-Dobreva, M; Harris, WP; Saulay, M; Engelhardt, M; Braun, S; Busset, MDD; Borad, MJ

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (4):

科室
- - 订阅+
  - 更多科室
工具
服务